Comparative Pharmacology
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus VIZAMYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENOMETHIONINE SE 75 versus VIZAMYL.
SELENOMETHIONINE SE 75 vs VIZAMYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopharmaceutical agent: selenium-75 decays by electron capture to arsenic-75 with emission of gamma photons. Used as a tracer for pancreatic imaging due to incorporation into pancreatic enzymes. Localizes in pancreas via protein synthesis.
Vizamyl is a radiopharmaceutical that binds to beta-amyloid plaques in the brain, enabling visualization via PET imaging.
0.185-0.37 MBq (5-10 μCi) intravenously as a single dose for pancreatic imaging.
For diagnostic imaging: 370 MBq (10 mCi) administered as a slow intravenous bolus (approximately 1 mL/sec).
None Documented
None Documented
Terminal half-life is approximately 50-60 days, reflecting slow turnover of selenomethionine incorporated into body proteins (e.g., skeletal muscle, erythrocytes).
Terminal elimination half-life is approximately 45-50 minutes in patients with normal renal function, allowing for rapid clearance and early imaging within 4 hours post-injection.
Primarily renal, with 20-30% excreted unchanged in urine; minor fecal elimination (<5%). The remainder is incorporated into endogenous proteins and long-term tissue stores.
Primarily renal excretion as unchanged drug (90-95%) with the remainder excreted via feces (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical